Quantitative X-ray microanalysis of alveolar macrophages after long-term treatment with amiodarone

Treatment with the iodine-containing antiarrhythmic drug, amiodarone, can cause pulmonary toxicity. Alveolar macrophages are particularly susceptible to formation of lipid-rich lamellar bodies in amiodarone-treated animals. Amiodarone and several of its metabolites accumulate in the cell. Previously...

Full description

Saved in:
Bibliographic Details
Published inExperimental and molecular pathology Vol. 52; no. 1; pp. 122 - 131
Main Authors Kirk, R.Gary, Lee, Ping, Reasor, Mark J.
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier Inc 01.02.1990
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Treatment with the iodine-containing antiarrhythmic drug, amiodarone, can cause pulmonary toxicity. Alveolar macrophages are particularly susceptible to formation of lipid-rich lamellar bodies in amiodarone-treated animals. Amiodarone and several of its metabolites accumulate in the cell. Previously, we have reported that the technique of X-ray microanalysis is useful in monitoring the distribution of iodine in freeze-dried cryosections of alveolar macrophages from Fischer 344 rats 24 hr after a single dose of amiodarone. In the present study, we examine the effects of longer term amiodarone treatment of 1 or 9 weeks. Substantial changes in iodine distribution occur in the cells with increasing length of drug treatment. High concentrations of iodine are found early in the lamellar bodies. The iodine levels in the nuclei slowly increase with the length of treatment, and after 9 weeks of treatment, approach those found in the lamellar bodies. It is possible that this accumulation of iodine in the nuclei is due to the presence of polar metabolites. In addition, the potassium concentration in the cell decreases and the sodium increases with treatment duration. These changes in cations are most likely due to altered ion transport in the macrophages by the inhibition of membrane NaK-ATPase by the drug and its principal metabolite, desethylamiodarone.
ISSN:0014-4800
1096-0945
DOI:10.1016/0014-4800(90)90064-K